Pulmonx

Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International and United States. The firm offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins in December 1995 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulmonx reports robust sales growth and eyes Japan expansion

Pulmonx shows strong sales growth and margin improvement in 2022
Balancing expenses and growth focus while navigating regulatory challenges
Confidence in future revenue growth through market expansion and account productivity

Pulmonx reports stellar Q1 sales growth and strategic initiatives

Pulmonx's Q1 2023 performance reflects robust sales growth, strategic commercial initiatives, and a focus on customer engagement. While challenges in profitability persist, the company's strong financial position and confidence in its strategy bode well for future growth and operational efficiency.

Pulmonx reports record sales in Q2 2023, eyes international expansion

Pulmonx delivered strong sales growth in Q2 2023, with a focus on strategic expansion and market development.
While facing financial challenges and losses, the company's emphasis on operational efficiency and international expansion presents growth opportunities.
With an updated revenue guidance and solid gross margin, Pulmonx is poised for continued growth and market penetration in the respiratory device sector.

Pulmonx achieves record revenue, eyes international expansion and patient outcomes

Pulmonx reported strong revenue growth in Q3 2023, driven by U.S. sales and a focus on commercial strategy, with increased account productivity and new center openings.
While facing challenges in international sales and regulatory differences in Europe, the company remains optimistic about future growth and the potential of the AeriSeal program.
Opportunities lie in international expansion, positive patient outcomes expected from the CONVERT 2 study, and investments in the right people and referral centers for enhanced patient care.

Pulmonx reports record sales in Q4 2023, eyes revenue growth

Pulmonx's strong financial performance in Q4 2023 and full year 2023 reflects growth and potential.
The company's strategic focus on product development and market expansion presents opportunities for future revenue.
Challenges include increased R&D expenses and market penetration efforts.
Overall, Pulmonx's performance and future plans indicate a positive outlook for growth and innovation.

Pulmonx reports robust Q1 earnings, eyes global expansion for growth

Pulmonx's strong Q1 performance, focus on innovation, and strategic growth initiatives position the company for long-term success.
While facing challenges in achieving profitability and managing expenses, Pulmonx's market opportunities and financial discipline are key strengths.
The company's outlook for 2024 remains positive, supported by revenue guidance, operational efficiency, and a commitment to patient care.
Investors should monitor Pulmonx's progress in key trials, international expansion, and financial metrics to assess its growth trajectory.

Pulmonx achieves record sales, focuses on growth and efficiency

Pulmonx reported strong sales growth and operational improvements in Q2 2024, despite a net loss.
The company's focus on expanding patient access and driving workflow efficiencies positions it well for future growth.
While facing financial challenges, Pulmonx has opportunities to enhance profitability through cost management and market expansion.
Overall, Pulmonx's strategic initiatives and performance indicate a positive outlook for the company's future.

Pulmonx posts strong Q3 earnings, eyes global expansion opportunities

Pulmonx delivered strong financial performance in Q3 2024, driven by robust U.S. revenue and international growth, positioning the company for future success.
With a focus on innovation, market expansion, and financial discipline, Pulmonx is well-positioned to capitalize on growth opportunities and navigate challenges effectively.
The company's solid cash position, successful clinical trials, and strategic initiatives underscore its potential for sustained growth and market leadership.
Pulmonx's commitment to training, automation, and awareness building, coupled with global expansion plans, bodes well for long-term value creation and competitive advantage.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022.

Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results

REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2023 Healthcare Conference in New York on Thursday, March 2, 2023, at 10:15 AM PT / 1:15 PM ET.

Pulmonx to Present at the Citi 2023 Healthcare Conference

REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

REDWOOD CITY, Calif.--( BUSINESS WIRE )--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, has partnered with American Lung Association to provide education to patients and providers on Endobronchial Valves, a clinically proven treatment to help people with severe COPD/emphysema breathe easier.1 COPD has no cure and is the third leading cause of death worldwide. Individuals living with advanced disease often struggle with each breath and have a very poor quality of life, and traditionally have not had good treatment options once medication alone no longer controls the symptoms of the disease well.

American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema

REDWOOD CITY, Calif. & TOKYO--( BUSINESS WIRE )--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). The Zephyr Valve is a minimally invasive treatment option that can deliver significant benefits to patients including improvements in lung function, exercise capacity, and quality of life.1 Placed by bronchoscopy, with no cutting or incision, the valves are for patients who remain symptomatic despite optimal management including medications, pulmonary rehabilitation, and supplemental oxygen. Pulmonx intends to collaborate with the Japanese MHLW to gain reimbursement prior to commercialization in Japan to ensure broader access to its innovative and clinically proven treatment.

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET.

Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference

Pulmonx has an FDA-approved technology to treat severe emphysema. The company estimates its valve treatment is a $12 billion market opportunity.

Pulmonx: An Ideal Takeout Candidate

Pulmonx Corporation (NASDAQ:LUNG ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Laine Morgan - Investor Relations Glen French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Jason Bednar - Piper Sandler Operator Good afternoon and welcome to Pulmonx Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Pulmonx Corporation (LUNG) Q3 2022 Earnings Call Transcript

Investors are reacting negatively to the company's planned securities offering.

Why Pulmonx Stock Is Crashing Today

Pulmonx Corporation (LUNG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Pulmonx Corporation (LUNG) Q3 Earnings Expected to Decline

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 3, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report Third Quarter 2022 Financial Results on November 3, 2022

Axonics ModulationTechnologies Inc

Inspire Medical Systems Inc

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.

3 Medical Info System Stocks to Gain on Rising Demand for Digital Health

Pulmonx Corporation (LUNG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 27.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Pulmonx Corporation (LUNG)

REDWOOD CITY, Calif. & BARCELONA, Spain--(BUSINESS WIRE)---- $LUNG #COPD--CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in fireside chats at two upcoming investor conferences. Pulmonx management is scheduled to participate in the 2022 Wells Fargo Healthcare Conference in Boston on Wednesday, September 7, 2022, at 6:10am PT / 9:10am ET and the Morgan Stanley 20th Annual Global Healthcare Conference in New Y

Pulmonx to Present at Upcoming September Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 78.6% in Pulmonx Corporation (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 79% Upside in Pulmonx Corporation (LUNG): Here's What You Should Know

Pulmonx Corporation (NASDAQ:LUNG ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Glen French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Travis Steed - BofA Securities David Ko - Canaccord Genuity Larry Biegelsen - Wells Fargo Joseph Downing - PSC Joanne Wuensch - Citi Operator Good afternoon, and welcome to Pulmonx Second Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Pulmonx Corporation (LUNG) CEO Glen French on Q2 2022 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter ended June 30, 2022.

Pulmonx Reports Second Quarter 2022 Financial Results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 10, 2022, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://invest

Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Participants are required to register online, and should do so at minimum 15 minutes b

Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022

The consensus price target hints at an 117.5% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Pulmonx Corporation (LUNG) Climb 117% to Reach the Level Wall Street Analysts Expect?

FDA approved technology to treat severe emphysema. Sizeable $12 billion market opportunity.

Pulmonx: Interesting Technology But Struggling With Adoption

Pulmonx Corporation (NASDAQ:LUNG ) Q1 2022 Results Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Brian Johnston - VP, Investor Relations, Gilmartin Group Glendon French - President & Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Operator Thank you for standing by, and welcome to the Pulmonx Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only.

News for Pulmonx Stock (LUNG)